Roche Eyes Liquid Biopsy As A Boost To Drug Development, Cancer Monitoring

The Gray Sheet spoke to Roche Molecular Diagnostic's top researcher, Walter Koch, about the promise of liquid biopsy soon after FDA approved its first liquid-biopsy companion diagnostic, Roche's cobas test for the cancer drug Tarceva.

Roche Diagnostics Corp.is bullish about the prospects of liquid biopsies both as a tool to remake cancer treatment monitoring and diagnostics, but also, in particular, to improve cancer trial clinical trials.

In an interview with The Gray Sheet, Walter Koch, a vice president and head of research of Roche's molecular diagnostics unit, says that replacing tissue biopsies with less-invasive liquid biopsies...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D